147 related articles for article (PubMed ID: 27739311)
1. [Prognostic and Predictive Factors for Pancreatic Adenocarcinoma].
Karásek P; Hermanová M
Klin Onkol; 2016; 29(5):336-341. PubMed ID: 27739311
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
[TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive markers in pancreatic adenocarcinoma.
Le N; Sund M; Vinci A;
Dig Liver Dis; 2016 Mar; 48(3):223-30. PubMed ID: 26769569
[TBL] [Abstract][Full Text] [Related]
4. Prognostic markers in pancreatic ductal adenocarcinomas.
Hezel AF; Bardeesy N
Cancer Biol Ther; 2008 Sep; 7(9):1360-1. PubMed ID: 18836287
[No Abstract] [Full Text] [Related]
5. Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma.
Niedergethmann M; Wostbrock B; Sturm JW; Willeke F; Post S; Hildenbrand R
Pancreas; 2004 Oct; 29(3):204-11. PubMed ID: 15367886
[TBL] [Abstract][Full Text] [Related]
6. SPARC mRNA expression as a prognostic marker for pancreatic adenocarcinoma patients.
Miyoshi K; Sato N; Ohuchida K; Mizumoto K; Tanaka M
Anticancer Res; 2010 Mar; 30(3):867-71. PubMed ID: 20393008
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
[TBL] [Abstract][Full Text] [Related]
8. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
Orth M; Metzger P; Gerum S; Mayerle J; Schneider G; Belka C; Schnurr M; Lauber K
Radiat Oncol; 2019 Aug; 14(1):141. PubMed ID: 31395068
[TBL] [Abstract][Full Text] [Related]
9. Label-free proteomics reveals serum proteins whose levels differ between pancreatic ductal adenocarcinoma patients with short or long survival.
Holm M; Saraswat M; Joenväärä S; Seppänen H; Renkonen R; Haglund C
Tumour Biol; 2020 Jun; 42(6):1010428320936410. PubMed ID: 32586207
[TBL] [Abstract][Full Text] [Related]
10. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients.
Martinez-Useros J; Li W; Georgiev-Hristov T; Fernandez-Aceñero MJ; Borrero-Palacios A; Perez N; Celdran A; Garcia-Foncillas J
Pathol Oncol Res; 2019 Jan; 25(1):269-278. PubMed ID: 29101736
[TBL] [Abstract][Full Text] [Related]
11. Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy.
Murata Y; Hamada T; Kishiwada M; Ohsawa I; Mizuno S; Usui M; Sakurai H; Tabata M; Ii N; Inoue H; Shiraishi T; Isaji S
J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):413-25. PubMed ID: 21898089
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.
McGuigan A; Kelly P; Turkington RC; Jones C; Coleman HG; McCain RS
World J Gastroenterol; 2018 Nov; 24(43):4846-4861. PubMed ID: 30487695
[TBL] [Abstract][Full Text] [Related]
13. Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future.
Barhli A; Cros J; Bartholin L; Neuzillet C
Dig Liver Dis; 2018 Oct; 50(10):979-990. PubMed ID: 30205952
[TBL] [Abstract][Full Text] [Related]
14. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.
Biankin AV; Morey AL; Lee CS; Kench JG; Biankin SA; Hook HC; Head DR; Hugh TB; Sutherland RL; Henshall SM
J Clin Oncol; 2002 Dec; 20(23):4531-42. PubMed ID: 12454109
[TBL] [Abstract][Full Text] [Related]
15. Use of Salivary MicroRNAs for Diagnosis of Solid Cancers.
Kubíčková A; Slabý O
Klin Onkol; 2018; 31(4):249-259. PubMed ID: 30541306
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma.
Yang L; Yang Z; Li D; Liu Z; Zou Q; Yuan Y; Xu H
Pathol Oncol Res; 2018 Oct; 24(4):899-906. PubMed ID: 28921449
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for actual long-term survival in the era of multidisciplinary treatment for pancreatic ductal adenocarcinoma.
Nakagawa K; Akahori T; Nishiwada S; Nagai M; Nakamura K; Tanaka T; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Ikeda N; Sho M
Langenbecks Arch Surg; 2018 Sep; 403(6):693-700. PubMed ID: 30218193
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
Park H; Lee Y; Lee H; Kim JW; Hwang JH; Kim J; Yoon YS; Han HS; Kim H
Tumour Biol; 2017 Oct; 39(10):1010428317718403. PubMed ID: 29025374
[TBL] [Abstract][Full Text] [Related]
20. Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review.
Vellan CJ; Jayapalan JJ; Yoong BK; Abdul-Aziz A; Mat-Junit S; Subramanian P
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
